Document is current

Article History

Received: 25 March 2025

Accepted: 24 March 2026

First Online: 3 April 2026

Declarations

:

: I.N. reports employment with Flatiron Health, Inc., an independent member of the Roche group, and stock ownership in Roche. R.U. has consulting/advisory relationships with Eisai, Sawai Pharmaceutical, SBI Pharmaceuticals, Daiichi Sankyo, Statcom, Toregem Biopharma, and EPSCorporation and has received honoraria from Janssen Pharmaceutical, SAS Institute Japan, and Nippon Kayaku outside the submitted work. H.I. received personal fees from Astellas, AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Nippon Kayaku, Ohara, Sawai, Taiho, and Yakult outside the submitted work. S.O. received research funding from Abbvie, Amgen, AstraZeneca, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Pfizer, MSD, Sanofi, Taiho, and Takeda and lecture fees from AstraZeneca, Chugai, MSD, and Takeda outside the submitted work. S.K. received honoraria fees from AstraZeneca, Chugai, Taiho, Kyorin, Daiichi Sankyo, Bristol-Myers Squibb, MSD, and Amgen outside the submitted work. The remaining authors declare no competing and financial interests.